AG˹ٷ

STOCK TITAN

[8-K] Biohaven Ltd. Reports Material Event

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
8-K
Rhea-AI Filing Summary

Biohaven Ltd. furnished a Current Report on Form 8-K to announce a press release reporting its financial results for the second quarter ended June 30, 2025. The press release is furnished as Exhibit 99.1 and the cover page of the report is provided in Inline XBRL as Exhibit 104.

The filing states the information in Item 2.02 and Exhibit 99.1 is furnished and shall not be deemed "filed" for purposes of Section 18 of the Exchange Act, and is not incorporated by reference in other filings except by specific reference. The registrant is organized in the British Virgin Islands, its common shares trade under BHVN on the New York Stock Exchange, and the report is signed by Chief Financial Officer Matthew Buten.

Biohaven Ltd. ha presentato un Current Report sul Form 8-K per comunicare un comunicato stampa relativo ai risultati finanziari del secondo trimestre chiuso al 30 giugno 2025. Il comunicato è fornito come Exhibit 99.1 e la pagina di copertina del rapporto è stata resa disponibile in Inline XBRL come Exhibit 104.

La documentazione specifica che le informazioni contenute nell'Item 2.02 e nell'Exhibit 99.1 sono rese a titolo di 'furnished' e non devono essere considerate come 'filed' ai fini della Sezione 18 dell'Exchange Act, né sono incorporate per riferimento in altri documenti se non mediante espressa indicazione. La società è costituita nelle British Virgin Islands, le sue azioni ordinarie sono negoziate con il ticker BHVN sul New York Stock Exchange, e il rapporto è firmato dal Chief Financial Officer Matthew Buten.

Biohaven Ltd. presentó un Current Report en el Formulario 8-K para anunciar un comunicado de prensa con los resultados financieros del segundo trimestre cerrado el 30 de junio de 2025. El comunicado se adjunta como Exhibit 99.1 y la portada del informe se ha proporcionado en Inline XBRL como Exhibit 104.

La presentación indica que la información del Item 2.02 y del Exhibit 99.1 se suministra ('furnished') y no debe considerarse 'filed' a efectos de la Sección 18 del Exchange Act, y no se incorpora por referencia en otros documentos salvo que exista una referencia específica. La registrante está constituida en las British Virgin Islands, sus acciones ordinarias cotizan con el símbolo BHVN en la New York Stock Exchange, y el informe está firmado por el Director Financiero Matthew Buten.

Biohaven Ltd.� Form 8-K� 따른 Current Report� 제출하여 2025� 6� 30일로 종료� 2분기 재무 실적� 알리� 보도자료� 공시했습니다. 해당 보도자료� Exhibit 99.1� 첨부되어 있으�, 보고� 표지� Inline XBRL 형식� Exhibit 104� 제공되었습니�.

제출서에� Item 2.02 � Exhibit 99.1� 정보가 'furnished'� 것으�, Exchange Act� Section 18� 따라 'filed'� 간주되지 않으�, 명시� 참조가 있는 경우� 제외하고 다른 제출서류� 참조� 포함되지 않는다고 명시되어 있습니다. 등록회사� British Virgin Islands� 설립되어 있으�, 보통주는 New York Stock Exchange에서 BHVN으로 거래되고, 보고서는 최고재무책임�(Chief Financial Officer) Matthew Buten� 서명으로 제출되었습니�.

Biohaven Ltd. a déposé un Current Report sur le Formulaire 8-K pour annoncer un communiqué de presse présentant ses résultats financiers pour le deuxième trimestre clos le 30 juin 2025. Le communiqué est fourni en tant que Exhibit 99.1 et la page de couverture du rapport est fournie en Inline XBRL en tant que Exhibit 104.

Le dépôt précise que les informations figurant à l'Item 2.02 et dans l'Exhibit 99.1 sont « furnished » et ne doivent pas être considérées comme « filed » aux fins de la Section 18 de l'Exchange Act, et ne sont pas incorporées par référence dans d'autres dépôts sauf mention expresse. L'entité est constituée dans les British Virgin Islands, ses actions ordinaires se négocient sous le symbole BHVN à la New York Stock Exchange, et le rapport est signé par le directeur financier Matthew Buten.

Biohaven Ltd. hat einen Current Report auf Form 8-K eingereicht, um eine Pressemitteilung mit den Finanzergebnissen für das am 30. Juni 2025 endende zweite Quartal bekanntzugeben. Die Pressemitteilung ist als Exhibit 99.1 beigefügt und die Titelseite des Berichts wurde im Inline XBRL als Exhibit 104 bereitgestellt.

In der Einreichung wird erklärt, dass die Informationen in Item 2.02 und in Exhibit 99.1 als 'furnished' gelten und nicht im Sinne von Section 18 des Exchange Act als 'filed' anzusehen sind und nicht durch Verweis in andere Einreichungen aufgenommen werden, es sei denn, es liegt eine ausdrückliche Bezugnahme vor. Der Registrant ist in den British Virgin Islands organisiert, seine Stammaktien werden unter BHVN an der New York Stock Exchange gehandelt, und der Bericht ist vom Chief Financial Officer Matthew Buten unterzeichnet.

Positive
  • None.
Negative
  • None.

Insights

TL;DR: Routine earnings disclosure; 8-K furnishes a press release with Q2 results but contains no financial figures itself.

The Form 8-K furnishes rather than files a press release announcing results for the quarter ended June 30, 2025, and attaches Exhibit 99.1 plus an Inline XBRL cover page as Exhibit 104. Because the body of the 8-K contains no revenue, earnings, or guidance figures, the filing itself does not add quantitative information for valuation or modeling. Investors must review the press release exhibit for material metrics; absent those figures, this filing is neutral in impact.

TL;DR: Procedural disclosure confirming a press release and limiting Section 18 liability; follows standard governance practice.

The registrant explicitly states the furnished material is not "filed" under Section 18, which limits the 8-K text's incorporation and related liability. The inclusion of Exhibit 99.1 and the Inline XBRL cover page, plus a signature by the CFO, align with routine SEC disclosure procedures. There are no governance actions, officer changes, or material transactions disclosed in this report.

Biohaven Ltd. ha presentato un Current Report sul Form 8-K per comunicare un comunicato stampa relativo ai risultati finanziari del secondo trimestre chiuso al 30 giugno 2025. Il comunicato è fornito come Exhibit 99.1 e la pagina di copertina del rapporto è stata resa disponibile in Inline XBRL come Exhibit 104.

La documentazione specifica che le informazioni contenute nell'Item 2.02 e nell'Exhibit 99.1 sono rese a titolo di 'furnished' e non devono essere considerate come 'filed' ai fini della Sezione 18 dell'Exchange Act, né sono incorporate per riferimento in altri documenti se non mediante espressa indicazione. La società è costituita nelle British Virgin Islands, le sue azioni ordinarie sono negoziate con il ticker BHVN sul New York Stock Exchange, e il rapporto è firmato dal Chief Financial Officer Matthew Buten.

Biohaven Ltd. presentó un Current Report en el Formulario 8-K para anunciar un comunicado de prensa con los resultados financieros del segundo trimestre cerrado el 30 de junio de 2025. El comunicado se adjunta como Exhibit 99.1 y la portada del informe se ha proporcionado en Inline XBRL como Exhibit 104.

La presentación indica que la información del Item 2.02 y del Exhibit 99.1 se suministra ('furnished') y no debe considerarse 'filed' a efectos de la Sección 18 del Exchange Act, y no se incorpora por referencia en otros documentos salvo que exista una referencia específica. La registrante está constituida en las British Virgin Islands, sus acciones ordinarias cotizan con el símbolo BHVN en la New York Stock Exchange, y el informe está firmado por el Director Financiero Matthew Buten.

Biohaven Ltd.� Form 8-K� 따른 Current Report� 제출하여 2025� 6� 30일로 종료� 2분기 재무 실적� 알리� 보도자료� 공시했습니다. 해당 보도자료� Exhibit 99.1� 첨부되어 있으�, 보고� 표지� Inline XBRL 형식� Exhibit 104� 제공되었습니�.

제출서에� Item 2.02 � Exhibit 99.1� 정보가 'furnished'� 것으�, Exchange Act� Section 18� 따라 'filed'� 간주되지 않으�, 명시� 참조가 있는 경우� 제외하고 다른 제출서류� 참조� 포함되지 않는다고 명시되어 있습니다. 등록회사� British Virgin Islands� 설립되어 있으�, 보통주는 New York Stock Exchange에서 BHVN으로 거래되고, 보고서는 최고재무책임�(Chief Financial Officer) Matthew Buten� 서명으로 제출되었습니�.

Biohaven Ltd. a déposé un Current Report sur le Formulaire 8-K pour annoncer un communiqué de presse présentant ses résultats financiers pour le deuxième trimestre clos le 30 juin 2025. Le communiqué est fourni en tant que Exhibit 99.1 et la page de couverture du rapport est fournie en Inline XBRL en tant que Exhibit 104.

Le dépôt précise que les informations figurant à l'Item 2.02 et dans l'Exhibit 99.1 sont « furnished » et ne doivent pas être considérées comme « filed » aux fins de la Section 18 de l'Exchange Act, et ne sont pas incorporées par référence dans d'autres dépôts sauf mention expresse. L'entité est constituée dans les British Virgin Islands, ses actions ordinaires se négocient sous le symbole BHVN à la New York Stock Exchange, et le rapport est signé par le directeur financier Matthew Buten.

Biohaven Ltd. hat einen Current Report auf Form 8-K eingereicht, um eine Pressemitteilung mit den Finanzergebnissen für das am 30. Juni 2025 endende zweite Quartal bekanntzugeben. Die Pressemitteilung ist als Exhibit 99.1 beigefügt und die Titelseite des Berichts wurde im Inline XBRL als Exhibit 104 bereitgestellt.

In der Einreichung wird erklärt, dass die Informationen in Item 2.02 und in Exhibit 99.1 als 'furnished' gelten und nicht im Sinne von Section 18 des Exchange Act als 'filed' anzusehen sind und nicht durch Verweis in andere Einreichungen aufgenommen werden, es sei denn, es liegt eine ausdrückliche Bezugnahme vor. Der Registrant ist in den British Virgin Islands organisiert, seine Stammaktien werden unter BHVN an der New York Stock Exchange gehandelt, und der Bericht ist vom Chief Financial Officer Matthew Buten unterzeichnet.

0001935979false00019359792025-08-112025-08-11

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): August 11, 2025
Biohaven Ltd.
(Exact name of registrant as specified in its charter)
British Virgin Islands001-41477Not applicable
(State or other jurisdiction of incorporation)(Commission File Number)(IRS Employer Identification No.)
c/o Biohaven Pharmaceuticals, Inc.
215 Church Street
New Haven, Connecticut 06510
(Address of principal executive offices, including zip code)
(203) 404-0410
(Registrant’s telephone number, including area code)
Not applicable
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
 Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading symbolName of each exchange on which registered
Common Shares, no par valueBHVNNew York Stock Exchange
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company 
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐ 




Item 2.02    Results of Operations and Financial Condition.
On August 11, 2025, Biohaven Ltd. (the “Registrant”) issued a press release announcing its financial results for the second quarter ended June 30, 2025. A copy of this press release is furnished herewith as Exhibit 99.1 to this Current Report and is incorporated herein by reference.

In accordance with General Instruction B.2. of Form 8-K, the information in this Item 2.02, and Exhibit 99.1 hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liability of that section, nor shall it be deemed incorporated by reference in any of the Registrant’s filings under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, regardless of any incorporation language in such a filing, except as expressly set forth by specific reference in such a filing.

Item 9.01    Financial Statements and Exhibits.

(d) Exhibits

Exhibit NumberExhibit Description
99.1
Press Release, dated August 11, 2025, "Biohaven Reports Second Quarter 2025 Financial Results and Recent Business Developments."
104The cover page of this Current Report on Form 8-K formatted as Inline XBRL.

2


SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: August 11, 2025
Biohaven Ltd.
By:/s/ Matthew Buten
Matthew Buten
Chief Financial Officer


3

FAQ

What does the Biohaven (BHVN) 8-K disclose?

The 8-K furnishes a press release announcing Biohaven's financial results for the second quarter ended June 30, 2025, attached as Exhibit 99.1, and includes an Inline XBRL cover page as Exhibit 104.

Is the information in the 8-K considered "filed" under the Exchange Act?

No. The filing states the information in Item 2.02 and Exhibit 99.1 is furnished and shall not be deemed "filed" for purposes of Section 18 of the Exchange Act.

Does the 8-K itself include financial figures for Q2 2025?

No. The 8-K text notifies of a press release with results but does not include specific financial metrics; those would be in Exhibit 99.1.

Where is Biohaven incorporated and where do its shares trade?

Biohaven Ltd. is organized in the British Virgin Islands and its common shares trade under the ticker BHVN on the New York Stock Exchange.

Who signed the 8-K for Biohaven?

The report is signed on behalf of Biohaven by Matthew Buten, Chief Financial Officer.
Biohaven

NYSE:BHVN

BHVN Rankings

BHVN Latest News

BHVN Latest SEC Filings

BHVN Stock Data

1.54B
86.90M
11.96%
90.74%
13.21%
Biotechnology
Pharmaceutical Preparations
United States
NEW HAVEN